<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03515694</url>
  </required_header>
  <id_info>
    <org_study_id>BRIDION_ERASME</org_study_id>
    <nct_id>NCT03515694</nct_id>
  </id_info>
  <brief_title>Minimal Optimal Dose of Sugammadex in Elective Surgery</brief_title>
  <official_title>Minimal Optimal Dose of Sugammadex in Elective Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Time of appearance of TOF Ratio &gt;0,9 with different doses of Sugammadex&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: monocentric, prospective, controlled, randomized, double-blind study Inclusion&#xD;
      criteria: women and men&gt; 18 years old, elective surgery, BMI &lt;30, patients giving consent to&#xD;
      free and informed participation in writing;&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  minor patients;&#xD;
&#xD;
        -  Patients refusing to sign the consent;&#xD;
&#xD;
        -  Patients included in another protocol within 3 months;&#xD;
&#xD;
        -  Pregnant or lactating patients;&#xD;
&#xD;
        -  Patients with a history of allergy to Sugammadex;&#xD;
&#xD;
        -  Patients with known neuromuscular disease;&#xD;
&#xD;
        -  Patients with renal or hepatic impairment.&#xD;
&#xD;
      Course of the study :&#xD;
&#xD;
        -  40 patients will be recruited at the time of the anesthesia consultation and randomized&#xD;
           to double blind in 8 groups (the day before surgery)&#xD;
&#xD;
        -  All patients will benefit from general anesthesia. Anesthetic management&#xD;
&#xD;
           (1- 3mg / kg / IV propofol, 0.2 Î¼g / IV sufentanil, 0.6 mg / kg rocuronium and&#xD;
           maintenance anesthesia with sevoflurane) will be standardized for all patients.&#xD;
&#xD;
        -  Upon administration of rocuronium the acceleromyography transducer will be attached to&#xD;
           the distal phalanx of the thumb, and repeated TOF stimulation will be applied to the&#xD;
           ulnar nerve wrist at intervals of 15 seconds. Neuromuscular monitoring is continued&#xD;
           until the end of the anesthesia.&#xD;
&#xD;
        -  Once the first answer (1st twitch) appeared a dose of sugammadex will be administered&#xD;
           according to the group whose patient was randomized: Test Groups Control Groups Group 1:&#xD;
           Placebo + TOF 1 Group 1bis: Placebo + TOF2 Group 2: 0.5 mg / kg + TOF1 Group 2bis: 0.5&#xD;
           mg / kg + TOF2 Group 3: 1mg / kg + TOF1 Group 3bis: 1mg / kg + TOF2 Group 4: 2mg / kg +&#xD;
           TOF 1 Group 4bis: 2mg / kg + TOF 2&#xD;
&#xD;
        -  Then a standard dose of 4mg / kg will be administered at the end of the procedure before&#xD;
           awakening to all patients who have signs of residual curarization (TOF ratio &lt;0.9). The&#xD;
           pharmacy will be responsible for preparing the different doses of sugammadex, the&#xD;
           syringe will be carefully covered and packaged, will contain an equal volume so that the&#xD;
           anesthetists do not know which group the patient belongs to. Data collection: In real&#xD;
           time during the intervention by the anesthesiologist in charge of patient Method of&#xD;
           Analysis: Analysis of intent-to-treat data&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Actual">September 30, 2018</completion_date>
  <primary_completion_date type="Actual">September 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel, Double blind Monocentric Prospective Vs placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the recovery time of the ratio 0.9.</measure>
    <time_frame>1 hour</time_frame>
    <description>Evaluate the recovery time of the ratio 0.9.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of appearance of 4 responses to the TOF</measure>
    <time_frame>1 hour</time_frame>
    <description>Time of appearance of 4 responses to the TOF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the four-to-four ratio &lt;0.7 after total recovery.</measure>
    <time_frame>1 hour</time_frame>
    <description>Evaluate the four-to-four ratio &lt;0.7 after total recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Watch time at the recovery room.</measure>
    <time_frame>4 hours</time_frame>
    <description>Watch time at the recovery room.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Time of a TOF Ratio &gt;0,9</condition>
  <arm_group>
    <arm_group_label>Dose of 0mg/kg TOF1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose of 0mg/kg TOF2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose of 0 ,5mg/kg TOF1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose of 0,5mg/kg TOF2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose of 1mg/kg TOF1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose of 1mg/kg TOF2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose of 2mg/kg TOF1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose of 2mg/kg TOF2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex Injection [Bridion]</intervention_name>
    <description>Injection of 10mL of translucide solution</description>
    <arm_group_label>Dose of 0 ,5mg/kg TOF1</arm_group_label>
    <arm_group_label>Dose of 0,5mg/kg TOF2</arm_group_label>
    <arm_group_label>Dose of 0mg/kg TOF1</arm_group_label>
    <arm_group_label>Dose of 0mg/kg TOF2</arm_group_label>
    <arm_group_label>Dose of 1mg/kg TOF1</arm_group_label>
    <arm_group_label>Dose of 1mg/kg TOF2</arm_group_label>
    <arm_group_label>Dose of 2mg/kg TOF1</arm_group_label>
    <arm_group_label>Dose of 2mg/kg TOF2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        women and men&gt; 18 years of age Elective Surgery BMI &lt;30, patients who gave consent to free&#xD;
        and informed participation in writing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  minor patients;&#xD;
&#xD;
          -  patients refusing to sign consent;&#xD;
&#xD;
          -  patients included in another protocol within 3 months;&#xD;
&#xD;
          -  pregnant or nursing patients;&#xD;
&#xD;
          -  patients with a history of allergy to Sugammadex;&#xD;
&#xD;
          -  patients with known neuromuscular disease&#xD;
&#xD;
          -  patients with renal or hepatic impairment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy FERNANDEZ, Resident</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasme University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 23, 2018</study_first_submitted>
  <study_first_submitted_qc>April 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2018</study_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bridion</keyword>
  <keyword>Sugammadex</keyword>
  <keyword>TOF</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

